Your browser doesn't support javascript.
Correspondence on "Associations of baseline use of biologic or targeted synthetic DMARDs with COVID-19 severity in rheumatoid arthritis: results from the COVID-19 global rheumatology alliance physician registry" by Sparks et al.
van Vollenhoven, Ronald F; Tas, Sander W; Nurmohamed, Michael T.
  • van Vollenhoven RF; Department of Rheumatology, Amsterdam Rheumatology and Immunology Center, Amsterdam, The Netherlands r.vanvollenhoven@amsterdamumc.nl.
  • Tas SW; Department of Rheumatology and Clinical Immunology, Amsterdam Rheumatology and immunology Center, Amsterdam University Medical Centres, Amsterdam, Noord-Holland, The Netherlands.
  • Nurmohamed MT; Rheumatology, Amsterdam UMC Locatie VUmc, Amsterdam, The Netherlands.
Ann Rheum Dis ; 2021 Aug 13.
Article in English | MEDLINE | ID: covidwho-1356918

Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Year: 2021 Document Type: Article Affiliation country: Annrheumdis-2021-221146

Similar

MEDLINE

...
LILACS

LIS


Full text: Available Collection: International databases Database: MEDLINE Type of study: Prognostic study Language: English Year: 2021 Document Type: Article Affiliation country: Annrheumdis-2021-221146